Identification of critical process parameters and its interplay with nanosuspension formulation prepared by top down media milling technology – A QbD perspective

References

• Kesisoglou F, Panmai S, Wu Y. Nanosizing–oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631–644.
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008;364:64–75.
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3–19.
   PubMed Web of Science ®Google Scholar
• Niwa T, Miura S, Danjo K. Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies - Development of particle design method. Int J Pharm 2011;405:218–227.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist AJ, Strimfors M. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm 2009;35:1479–1486.
   PubMed Web of Science ®Google Scholar
• Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008;3:295–309.
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev 2011;63:427–440.
   PubMed Web of Science ®Google Scholar
• Bisrat M, Nyström C. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int J Pharm 1988;47:223–231.
   Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M, Zheng T, Wang S. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm 2007;33:1332–1339.
   PubMed Web of Science ®Google Scholar
• Bhakay A, Merwade M, Bilgili E, Dave RN. Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water-soluble drugs. Drug Dev Ind Pharm 2011;37:963–976.
   PubMed Web of Science ®Google Scholar
• Muller RH, Moschwitzer J, Bushrab FN. Manufacturing of nanoparticles by milling and homogenization techniques. Nanoparticle Technology for Drug Delivery 2006;159:21–51.
   Google Scholar
• Li W, Yang Y, Tian Y, Xu X, Chen Y, Mu L et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride Nanosuspension. Int J Pharm 2011;408:157–162.
   PubMed Web of Science ®Google Scholar
• Juhnke M, Märtin D, John E. Generation of wear during the production of drug nanosuspensions by wet media milling. Eur J Pharm Biopharm 2012;81:214–222.
   PubMed Web of Science ®Google Scholar
• Li X, Gu L, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm 2009;35:827–833.
   PubMed Web of Science ®Google Scholar
• Ambrus R, Kocbek P, Kristl J, Sibanc R, Rajkó R, Szabó-Révész P. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int J Pharm 2009;381:153–159.
   PubMed Web of Science ®Google Scholar
• Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 2009;377:185–198.
   PubMed Web of Science ®Google Scholar
• Singh SK, Srinivasan KK, Gowthamarajan K, Singare DS, Prakash D, Gaikwad NB. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur J Pharm Biopharm 2011;78:441–446.
   PubMed Web of Science ®Google Scholar
• Singarea DS, Marellaa S, Gowthamrajan K, Kulkarni GT, Vooturia R, Rao PS. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int J Pharm 2010;402:213–220.
   PubMed Web of Science ®Google Scholar
• Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res 2008;25:781–791.
   PubMed Web of Science ®Google Scholar
• Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm 2011;409:260–268.
   PubMed Web of Science ®Google Scholar
• Rajebahadur M, Zia H, Nues A, Lee C. Mechanistic study of solubility enhancement of nifedipine using vitamin E TPGS or solutol HS-15. Drug Deliv 2006;13:201–206.
   PubMed Web of Science ®Google Scholar
• Keck CM. Particle size analysis of nanocrystals: improved analysis method. Int J Pharm 2010;390:3–12.
   PubMed Web of Science ®Google Scholar
• Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 2009;380:216–222.
   PubMed Web of Science ®Google Scholar
• Verma S, Huey BD, Burgess DJ. Scanning probe microscopy method for nanosuspension stabilizer selection. Langmuir 2009;25:12481–12487.
   PubMed Web of Science ®Google Scholar
• Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm 2005;299:167–177.
   PubMed Web of Science ®Google Scholar
• Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le Lamer S et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm 2006;64:360–368.
   PubMed Web of Science ®Google Scholar